Created by President John F. Kennedy in 1961, the "E" and "E Star" Awards are presented each year to clients or partners of their local Commercial Service offices. Entrants are nominated by the local Department of Commerce offices with whom they work. The awards are the highest recognition any U.S. company or organization may receive for supporting U.S. exports.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology--alleviating pain, restoring health, and extending life for millions of people around the world.

SOURCE: Medtronic, Inc.

Medtronic, Inc. 
Jeff Warren, 763-505-2696 
Investor Relations 
or 
Chuck Grothaus, 763-505-2614 
Public Relations

In a release, the Company noted:

In an oral presentation entitled, "The Onset trial of sensor-enhanced CSII in children with new onset type 1 diabetes," results of a prospective, randomized, multi-center trial were shared. The physician-initiated study, performed in five pediatric centers, assessed whether children (ages 1-16) newly diagnosed with type 1 diabetes could achieve improved glycemic control using an insulin pump augmented with Personal continuous glucose monitoring (CGM), known as the MiniMed Paradigm REAL-Time System, compared to a control group using a conventional insulin pump with self monitoring of blood glucose (SMBG).

"It is quite evident that children with type 1 diabetes can benefit from using insulin pump therapy with real-time continuous glucose monitoring at the onset of their disease," said Thomas Danne, M.D., lead investigator and chief physician at the "Auf der Bult" Diabetes Center for Children and Adolescents in Hanover, Germany. "In fact, we noted evidence that reducing glycemic variability has an effect on the pancreas, preserving beta cell function, which likely will improve diabetes outcomes over the long-term in these children."

A total of 160 patients in this Medtronic-supported study were randomized to use conventional insulin pump therapy with SMBG or an insulin pump with Personal CGM for 12 months. Key results highlighted during the oral presentation include:

- Insulin pump therapy at diabetes onset results in lower A1C values (average blood glucose) compared to historical controls (the use of insulin injections during the first 12 months after diagnosis), and improves psychological well being.

- The sub-group of patients using Personal CGM regularly (at least one glucose sensor per week) experienced significantly lower A1C values (0.5 percent, p=0.032) during the first year compared to the conventional insulin pump group.

- There were significantly fewer episodes of severe hypoglycemia in patients using an insulin pump with Personal CGM compared to those using conventional insulin pumps.

- In patients using Personal CGM, more frequent glucose sensor use during the first year was associated with significantly less C-peptide loss, and C-peptide values at 12 months were significantly higher in adolescents (12-16 years). In addition, glycemic variability (calculated by mean amplitude glucose excursion, MAGE) was significantly lower compared to the group using a conventional insulin pump with SMBG.

The Onset trial, conducted in Austria, France, Germany, and Poland, adds to the growing body of evidence that demonstrates using Personal CGM on a regular basis improves glycemic control.

The MiniMed Paradigm REAL-Time System is the world's only system to integrate an insulin pump with Personal CGM. Patients using Personal CGM are able to view glucose sensor data and use this information to understand how diet, exercise, medications and lifestyle affect glucose levels. By viewing graphs and receiving alerts when glucose levels are becoming too high or too low, patients can make more informed therapy decisions to maintain near-normal the world leader in glucose control.

The Diabetes business at Medtronic provides diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software, as well as 24/7 consumer and professional service and support.

((Comments on this story may be sent to health@closeupmedia.com))

With intra-operative imaging information, neurosurgeons have more confidence to achieve maximum tumor resection, while avoiding critical areas of the brain. Use of the PoleStar system may also reduce the need for revision surgeries and the length of stay at the hospital for the patient, the company added.

Jim Cloar, vice president and general manager of the navigation division, part of the surgical technologies business at Medtronic, said: "This is the next generation of intra-operative MRI providing flexibility, enhanced ergonomics and confidence in the achievement of surgical goals.

"With its unique compact design, the PoleStar surgical MRI system allows neurosurgeons to benefit from intra-operative MRI without the compromises inherent in other systems, such as extensive renovation of the operating room or restrictions upon the surgeons' choice of instruments."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon